Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2026 Guidance Lifted

04:50 PM EST, 11/05/2026 (MT Newswires) -- Halozyme Therapeutics (HALO) reported Q3 adjusted earnings late Thursday of $2.39 per diluted share, compared with $1.72 a year earlier. Analysts polled by FactSet expected $2.30. Revenue in the three months ended Sept. 30 was $493 million, compared with $354.3 million a year earlier. Analysts projected $491.6 million. The company said it expects 2026 adjusted earnings in the range of $8.75 to $9.05, compared with its previous guidance of $8.65 to $9.00. Analysts expect $8.62. Revenue for the full year is slated to be between $1.86 billion to $1.93 billion, compared with $1.84 billion to $1.91 billion previously. Analysts expect $1.88 billion.